Fecal microbiota transplantation: an update on the advances in the treatment of complex diseases

1Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
2Centro per le Malattie dell’Apparato Digerente (CeMAD), UOS di Malattie Infiammatorie Croniche Intestinali, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy.
3Dipartimento di Medicina e Scienze dell’Invecchiamento, Università degli studi “G. D’Annunzio”, Chieti-Pescara, Chieti, Italy.
4Center for Advanced Studies and Technology (CAST), Università degli studi “G. D’Annunzio”, Chieti-Pescara, Chieti, Italy.


In addition to its proven effectiveness in the treatment of recurrent Clostridium difficile infections (rCDI), fecal microbiota transplantation (FMT) is on the rise to become one of the most studied innovative therapies for the treatment of several complex diseases. This review aims to discuss the many promising applications of FMT in intestinal diseases such as inflammatory bowel diseases (IBD) and extraintestinal diseases such as neuropsychiatric disorders, metabolic syndrome, and autoimmune diseases. For each disease group, preclinical data will be presented in addition to clinical trial evidence.

Corresponding author:

Publication history:

Submission date: 8th Dec, 2022
Revised on: 12th Dec, 2022
Accepted on: 15th Dec, 2022
Published online: 10th Jan, 2023

Related articles

Alcohol use disorder (AUD) is frequent globally and is responsible for more than 5% of the global burden of disease and mortality.